Overview

Erenumab For Treatment of Hemicrania Continua

Status:
Recruiting

Trial end date:
2022-09-30

Target enrollment:

Participant gender:

Summary

This research is being conducting to learn if the study drug erenumab is successful in treating hemicrania continua. The study is also evaluating the safety and tolerability of erenumab in individuals being treated for hemicrania continua.

Phase:

Phase 2

Details

Lead Sponsor:

Mayo Clinic

Treatments:

Antibodies, Monoclonal
Erenumab